Africa · special
In Meliandou, a village in forested Guinea near Guéckédou, some fifty metres from the house of a two-year-old boy stood a large hollow tree where children went to play. The boy fell ill in December 2013 and was the first known case of the epidemic. On 24 March 2014 the tree caught fire, and from the trunk fell what villagers called a rain of bats. In ash and soil collected on the spot, Marí Saéz's group found the DNA of Mops condylurus, a small insect-eating bat, in five of eleven samples. The study appeared in 2015 in EMBO Molecular Medicine.
The same authors, however, found no virus in any of the bats they examined. The link between the tree and the first case remains a reasonable hypothesis, not a proof. It is a good place to start with Ebola, because ten years on much is known about this disease, yet some questions remain open. What did the West African epidemic leave behind, and what has it taught for the one now spreading in the Congo?
The final numbers come from the US Centers for Disease Control and Prevention, the CDC. In all there were 28,652 cases and 11,325 deaths. Sierra Leone had 14,124 cases, Liberia 10,678 and Guinea 3,814. The World Health Organization announced the outbreak on 23 March 2014 and on 8 August declared it an international health emergency. Guinea was declared free of transmission on 1 June 2016 and Liberia on 9 June. According to WHO's Africa office, the last flare-up in Guinea probably started from contact with a survivor's body fluids.
Italy had its two cases too. A doctor with the NGO Emergency, infected at a treatment centre in Sierra Leone, was admitted to Rome's Spallanzani hospital on 25 November 2014. He ended up in intensive care with pneumonia and malaria at once, was treated with an experimental antiviral, survivors' plasma and an antibody cocktail, and was discharged after 39 days. Spallanzani doctors described the case in 2015 in BMC Infectious Diseases. In May 2015 a nurse back from Sierra Leone fell ill in Sardinia, and according to WHO it was the first case detected on Italian soil. None of his nineteen contacts in Sassari fell ill.
The most disturbing finding concerns survivors. In 2019 the PREVAIL III study followed 966 survivors in Liberia and 2,350 of their antibody-negative contacts, publishing the results in the New England Journal of Medicine. A year after the illness survivors suffered far more often from memory loss, 29.2 per cent against 4.8, and from joint pain, 47.5 against 17.5. Uveitis, an inflammation of the eye, affected a third of them. In some men the virus's genetic material stayed in semen for up to 40 months.
That persistence has had consequences. In February 2021 a new outbreak appeared in Guinea, with 16 confirmed cases and 12 deaths. Analysing the genomes, Keita and colleagues showed in Nature that the virus was almost identical to that of 2013–2016. It had gathered 12 mutations where about 95 would have been expected, as if it had stood almost still for years. The authors conclude that the virus survived for years in the body of a recovered person, latent or replicating very slowly, before infecting others again. Ebola, in short, does not always end when an epidemic does. In 2026 two new studies described the neurological and psychological problems that remain in Liberia's survivors seven or eight years on.
The medical response came during the epidemic itself. In Guinea, in 2015, a vaccine made from an animal virus modified to carry an Ebola protein was tested by ring vaccination, vaccinating the contacts of each new case and the contacts of those contacts. In the randomised part of the trial, published in 2017 in The Lancet by Henao-Restrepo and colleagues, there were no cases among those vaccinated at once, against 16 among those who waited three weeks. The European Medicines Agency authorised it on 11 November 2019. In 2018–2020 the same vaccine was given to more than three hundred thousand people during the Kivu epidemic in the Congo, which counted 3,470 cases and 2,287 deaths. From there also came two monoclonal antibodies, now approved in the United States.
The vaccine and the two antibodies work, however, against only one species of the virus, Ebola Zaire. On 15 May 2026 the Democratic Republic of the Congo declared an epidemic caused by another species, Bundibugyo virus, and two days later WHO declared it an international health emergency. In August, according to a CDC report, only 15 to 20 per cent of new cases were known contacts, and 59 per cent of the dead had died outside treatment centres. It is the mark of an epidemic escaping contact tracing. With data to 26 October the European Centre for Disease Prevention and Control counts 10,141 confirmed cases and 4,928 deaths in the Congo, across eight provinces. Kenya, as of 25 October, had nine cases and two deaths, linked to a man who arrived in Nairobi from the Congo, and Nigeria had confirmed its first case on 20 October. For Europe the risk remains very low.
Against Bundibugyo there is no approved vaccine or treatment. On 31 August 2026 WHO ruled that the vaccine born in Guinea, built on the Zaire species, may be used against Bundibugyo only within research studies, because the evidence of cross-protection is not enough. In late October, in Bunia, Ituri, the TUMAINI trial began, testing vaccines by the same ring method used in Guinea. It starts with that vaccine and will later add two candidates designed for Bundibugyo, still in early tests on volunteers. A second WHO-backed trial, PARTNERS, has been comparing possible treatments since the summer. Ten years after West Africa, the clearest lesson is just this. Ring vaccination showed that an epidemic can be stopped, but each species of the virus needs its own weapon.
In Meliandou the hollow tree is gone, burned in March 2014. The vaccine tested a few kilometres away stopped the Zaire virus in Guinea and in the Congo. Bundibugyo is another species, and in Bunia the first people vaccinated in TUMAINI will show whether that vaccine also works against it or whether the vaccines built for the new virus are needed.
References
Marí Saéz A., Weiss S., Nowak K. et al., «Investigating the zoonotic origin of the West African Ebola epidemic», EMBO Molecular Medicine, 7(1), 17–23, 2015. doi: 10.15252/emmm.201404792 https://doi.org/10.15252/emmm.201404792
Centers for Disease Control and Prevention, «2014–2016 Ebola Outbreak in West Africa». https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html
Petrosillo N., Nicastri E., Lanini S. et al., INMI EBOV Team, «Ebola virus disease complicated with viral interstitial pneumonia: a case report», BMC Infectious Diseases, 15, 432, 2015. doi: 10.1186/s12879-015-1169-4 https://doi.org/10.1186/s12879-015-1169-4
Bertoli G., Mannazzu M., Madeddu G. et al., «Ebola virus disease: Case management in the Institute of Infectious Diseases, University Hospital of Sassari», Journal of Infection in Developing Countries, 10, 537–543, 2016. doi: 10.3855/jidc.8203 https://doi.org/10.3855/jidc.8203
PREVAIL III Study Group, Sneller M.C., Reilly C., Badio M. et al., «A Longitudinal Study of Ebola Sequelae in Liberia», New England Journal of Medicine, 380(10), 924–934, 2019. doi: 10.1056/NEJMoa1805435 https://doi.org/10.1056/NEJMoa1805435
Keita A.K., Koundouno F.R., Faye M. et al., «Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks», Nature, 597(7877), 539–543, 2021. doi: 10.1038/s41586-021-03901-9 https://doi.org/10.1038/s41586-021-03901-9
Billioux B.J., Reilly C., van Ryn C. et al., «Neurological Manifestations in Adult Survivors of Ebola Virus Disease», JAMA Neurology, 83(8), 739–748, 2026. doi: 10.1001/jamaneurol.2026.2112 https://doi.org/10.1001/jamaneurol.2026.2112
Badio M., Glayweon M., Van Ryn C. et al., «Long-term psychosocial sequelae of Ebola virus disease among survivors compared with contacts following the 2013–2016 epidemic in Liberia», PLOS Global Public Health, 6(1), e0005145, 2026. doi: 10.1371/journal.pgph.0005145 https://doi.org/10.1371/journal.pgph.0005145
Henao-Restrepo A.M., Camacho A., Longini I.M. et al., «Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)», The Lancet, 389(10068), 505–518, 2017. doi: 10.1016/S0140-6736(16)32621-6 https://doi.org/10.1016/S0140-6736(16)32621-6
European Medicines Agency, Ervebo, EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/ervebo
Kabasele D., Meyer E., Kabore I. et al., «Notes from the Field: 2026 Outbreak of Ebola Disease Caused by Bundibugyo Virus — Democratic Republic of the Congo, August 2026», MMWR, 75, 554–556, 2026. doi: 10.15585/mmwr.mm7535e1 https://doi.org/10.15585/mmwr.mm7535e1
Organizzazione mondiale della sanità, Disease Outbreak News 622, 23 ottobre 2026; European Centre for Disease Prevention and Control, aggiornamento sull'epidemia da virus Bundibugyo, 28 ottobre 2026 (dati al 26 ottobre; Kenya al 25 ottobre); OMS, Emergency guidance on the use of licensed Ebola vaccine during Bundibugyo virus disease outbreaks, 31 agosto 2026. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON622
Previous articles on ScienceOnline
Donati G., «One copy against malaria, two copies against the child», ScienceOnline, Africa · 2, 29 October 2026
Donati G., «Laetoli, the first steps in the ash», ScienceOnline, Africa · 1, 19 October 2026
*Board Member, SRSN (Roman Society of Natural Science)
Past Editor-in-Chief Italian Journal of Dermosurgery



